0.8520USD-3.07%Mkt Cap: 4.03M USDP/E: —Last update: 2026-05-22
Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also …
Industry Peers
Medical Devices151.38BUSDP/E 24.3
119.84BUSDP/E 36.2
86.12BUSDP/E 24.2
54.95BSEKP/E 101.9
53.92BSEKP/E 22.9
52.13BDKKP/E 22.1
50.54BUSDP/E 47.4
39.31BEURP/E 18.6
Indicators:|
Key Statistics
Company
Market Cap4.03M USD
Enterprise Value-3.28M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.88M USD
Revenue/Share—
Last Price0.8520 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees52
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.06
PEG—
EV/EBITDA0.42
EV/Revenue—
P/S—
P/B0.21
EPS (TTM)-6.92
EPS (Forward)-24.00
52W Range
0.72203% of range5.600
52W High5.600 USD
52W Low0.7220 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-52.85%
ROA-28.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.00M USD
CapEx (TTM)581.00K USD
FCF Margin—
FCF Yield-106.54%
Net Debt-6.19M USD
Net Debt/EBITDA0.78
Balance Sheet
Debt/Equity0.38
Current Ratio20.13
Quick Ratio19.57
Book Value/Sh6.650 USD
Cash/Share4.394 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:17
Split DateMar 7, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.88M
Float2.52M
Insiders1.46%
Institutions8.01%
Short Interest
Short Ratio0.8d
Short % Float2.25%
Short % Out.2.22%
Shares Short63.93K
Short (prev mo.)169.15K
Technical
SMA 500.9644 (-11.7%)
SMA 2002.040 (-58.2%)
Beta1.84
S&P 52W Chg28.31%
Avg Vol (30d)280.68K
Avg Vol (10d)350.24K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—